(Q37954709)

25 August 2017

title

The development of 13-valent pneumococcal conjugate vaccine and its possible use in adults (English)

1 reference

25 August 2017

Robert W Frenck

1

1 reference

25 August 2017

Sylvia Yeh

series ordinal

2

1 reference

25 August 2017

language of work or name

English

0 references

publication date

10 November 2011

1 reference

Expert Opinion on Biological Therapy

25 August 2017

published in

1 reference

25 August 2017

volume

12

1 reference

25 August 2017

issue

1

1 reference

25 August 2017

page(s)

63-77

1 reference

Clinical and economic burden of pneumococcal disease in older US adults.

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Burden of community-acquired pneumonia in North American adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Epidemiological differences among pneumococcal serotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Association of serotypes of Streptococcus pneumoniae with age in invasive pneumococcal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

The burden of community-acquired pneumonia in seniors: results of a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Global strategies to prevent bacterial pneumonia in adults with HIV disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

High rate of pneumococcal bacteremia in a prospective cohort of older children and adults in an area of high HIV prevalence in rural western Kenya

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Sickle cell trait, hemoglobin C trait, and invasive pneumococcal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Risk of invasive pneumococcal infections among working age adults with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Asthma as a risk factor for invasive pneumococcal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Increased risk of invasive pneumococcal disease in haematological and solid-organ malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Invasive pneumococcal disease in solid organ transplant recipients--10-year prospective population surveillance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Invasive pneumococcal disease in adult hematopoietic stem cell transplant recipients: a decade of prospective population-based surveillance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Pneumococcal vaccination for patients with COPD: current practice and future directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Protective Efficacy of Pneumococcal Polysaccharide Vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Advances in pneumococcal vaccines: what are the advantages for the elderly?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

The effectiveness of pneumococcal polysaccharide vaccines in adults: a systematic review of observational studies and comparison with results from randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Efficacy of pneumococcal vaccination in adults: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

The effectiveness of pneumococcal polysaccharide vaccination in HIV-infected adults: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Pneumococcal conjugated vaccine: PHiD-CV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with measles-mumps-rubella-varicella vaccine in children aged 12 to 16 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Exposure to children as a risk factor for bacteremic pneumococcal disease: changes in the post-conjugate vaccine era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Experience with pneumococcal conjugate vaccine in Norway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Superior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

A Randomized Clinical Trial Comparing Revaccination with Pneumococcal Conjugate Vaccine to Polysaccharide Vaccine among HIV‐Infected Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in alaska native adults 55-70 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Pneumococcal polysaccharide vaccination among adults aged 65 years and older, U.S., 1989-2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Achievement of healthy people 2010 objective for adult pneumococcal vaccination in an American Indian community

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Factors associated with pneumococcal and influenza vaccination in hospitalized people aged ≥65 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Low prevalence of prior streptococcus pneumoniae vaccination among potential lung transplant candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Pneumococcal conjugate vaccination for adults: why it's important for children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Pneumococcal vaccination of elderly adults: new paradigms for protection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Determining the optimal pneumococcal vaccination strategy for adults: is there a role for the pneumococcal conjugate vaccine?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Streptococcus pneumoniae protein vaccine candidates: properties, activities and animal studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Assessment of the safety of a third dose of pneumococcal polysaccharide vaccine in the Vaccine Safety Datalink population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

The Immunogenicity of 7‐Valent Pneumococcal Conjugate Vaccine versus 23‐Valent Polysaccharide Vaccine in Adults Aged 50–80 Years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Phase 1 trial of 13-valent pneumococcal conjugate vaccine in Japanese adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide–protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

The 23-valent pneumococcal polysaccharide vaccine does not provide additional serotype antibody protection in children who have been primed with two doses of heptavalent pneumococcal conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

The Changing Epidemiology of Invasive Pneumococcal Disease in Aboriginal and Non‐Aboriginal Western Australians from 1997 through 2007 and Emergence of Nonvaccine Serotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

The effect of routine vaccination on invasive pneumococcal infections in Canadian children, Immunization Monitoring Program, Active 2000–2007

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Invasive Pneumococcal Disease a Decade after Pneumococcal Conjugate Vaccine Use in an American Indian Population at High Risk for Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Hospitalizations for Invasive Pneumococcal Disease Among HIV-1–Infected Adolescents and Adults in the United States in the Era of Highly Active Antiretroviral Therapy and the Conjugate Pneumococcal Vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

The epidemiologic evidence underlying recommendations for use of pneumococcal polysaccharide vaccine among American Indian and Alaska Native populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Pneumococcal Conjugate Vaccine, Polysaccharide Vaccine, or Both for Adults? We’re Not There Yet

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Revaccination with a 23‐Valent Pneumococcal Polysaccharide Vaccine Induces Elevated and Persistent Functional Antibody Responses in Adults Aged ⩾65 Years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.636348

10.1517/14712598.2012.636348

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference